Sök i LIBRIS databas

  Utökad sökning


Sökning: onr:"swepub:oai:DiVA.org:umu-119404" > Donepezil in patien...

Donepezil in patients with severe Alzheimer's disease : double-blind, parallel-group, placebo-controlled study

Winblad, Bengt (författare)
Kilander, Lena (författare)
Uppsala universitet,Geriatrik
Eriksson, Sture (författare)
Umeå universitet,Geriatrik
visa fler...
Minthon, Lennart (författare)
Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups
Båtsman, Stellan (författare)
Wetterholm, Anna-Lena (författare)
Jarisson-Blixt, Catarina (författare)
Haglund, Anders (författare)
Jansson-Blixt, Catarina (författare)
Jarisson-Blixt, C (författare)
Eriksson, S (författare)
Winblad, B (författare)
Karolinska Institutet
Kilander, L (författare)
Batsman, S (författare)
Wetterholm, AL (författare)
Hoglund, A (författare)
Minthon, L (författare)
visa färre...
New York : Elsevier, 2006
Ingår i: The Lancet. - New York : Elsevier. - 0140-6736 .- 1474-547X. ; 367:9516, s. 1057-1065
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
  • Background The cholinesterase inhibitor donepezil is used to treat mild-to-moderate Alzheimer's disease. Its efficacy in severe dementia has not been assessed and is controversial. Our aim was to ascertain the effectiveness of donepezil in patients with severe Alzheimer's disease, by focusing primarily on cognition and activities of daily living.Methods We did a 6-month, double-blind, parallel-group, placebo-controlled study in 248 patients with severe Alzheimer's disease (mini mental state examination score 1-10) who were living in assisted care nursing homes ran by trained staff in Sweden. We assigned patients oral donepezil (5 mg per day for 30 days then up to 10 mg per day thereafter, n=128) or matched placebo (n=120). Our primary endpoints were change from baseline to month 6 in the severe impairment battery (SIB) and modified Alzheimer's Disease Cooperative Study activities of daily living inventory for severe Alzheimer's disease (ADCS-ADL-severe). We analysed outcomes for patients with data at baseline and at one or more other timepoints (modified intent-to-treat population) with last observation carried forward used to replace missing data.Findings 95 patients assigned donepezil and 99 patients assigned placebo completed the study. Patients treated with donepezil improved more in SIB scores and declined less in ADCS-ADL-severe scores at 6 months after initiation of treatment compared with baseline than did controls (least squares [LS] mean difference, 5.7,95% Cl 1.5-9.8; p=0.008, and 1.7, 0.2-3.2; p=0.03, respectively). The incidence of adverse events was comparable between groups (donepezil 82% [n=105] vs placebo 76% [n=91]), with most being transient and mild or moderate in severity. More patients discontinued treatment because of adverse events in the donepezil group (n=20) than in the placebo group (n=8).Interpretation Donepezil improves cognition and preserves function in individuals with severe Alzheimer's disease who live in nursing homes.


MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- General Practice (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Allmänmedicin (hsv//swe)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)


randomized controlled trial
severe impairment battery
demented patients
natural history

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy